CannMed Coffee Talk

We are excited to announce Bonni S. Goldstein, MD as the CannMed 2020’s Keynote Presenter in the Medicine Focus Area.

The title of Dr. Goldstein’s presentation is “Cannabis Medicine for Children.” She will be sharing her latest clinical findings, including promising results from her clinical practice focusing on the use of phytocannabinoid medicines to treat serious pediatric medical condition, including epilepsy, autism, and cancer.

You can hear Dr. Goldstein talk about her work on the latest episode of the CannMed Coffee Talk Podcast where she joins us as our guest. (Use the player at the bottom at the post to listen.)

As one of the most respected and experienced medical practitioners in this field, we are honored to have Dr. Goldstein once again take a major role at CannMed 2020. She has been a member of CannMed’s Advisory Board for three years and developed the CannMed Medical Practicum, a day-long workshop where healthcare providers, clinicians, caregivers, and patients learn the science of medical cannabis as well as practical advice about how to use various cannabinoids to treat a range of medical conditions.

A native of New Jersey, Dr. Goldstein received her undergraduate degree at Rutgers University, and her medical degree at Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey. She did her internship, residency, and chief residency at Children’s Hospital Los Angeles (CHLA). Dr. Goldstein was a Clinical Instructor in Pediatrics at USC School of Medicine, Emergency Transport Attending Physician at CHLA, and Emergency Medicine Attending Physician in the Pediatric Emergency Department at LA County - USC Medical Center.

Her interest in the science of medicinal cannabis was kindled more than ten years ago after witnessing its beneficial effects in a friend who was seriously ill. Since then, she has been evaluating and treating both adult and pediatric patients for the use of medicinal cannabis.

Dr. Goldstein is a sought-after lecturer to many patient support programs, including the Cancer Support Community in Southern California. She has been a featured speaker at CannMed since our first conference at Harvard University in 2016.  She has also presented at the Medical Cannabis for Autism conference at Children’s Hospital of Philadelphia and the International Congress on Clinical Trials in Cannabis in London, as well as many other cannabis conferences.

She is currently the Medical Director of Canna-Centers, a Los Angeles-based medical practice devoted to helping patients use cannabis medicine for serious and chronic medical conditions. She is also Medical Advisor to WeedMaps.com, a board member of the International Association of Cannabis as Medicine, and a member of the International Cannabinoid Research Society and the Society of Cannabis Clinicians.  She is the author of Cannabis Revealed and her second book, Cannabis is Medicine, will be published by Little, Brown Spark in September 2020.

We are thrilled to have Dr. Goldstein as one of our Keynote Speakers and look forward to her participation in the CannMed Medical Practicum!

Additional Resources:

Canna-Centers WebsiteWPA4AProject CBD Dr. Goldstein's CannMed Presentations - 2018 | 2017

In this episode of CannMed Coffee Talk we talk with Martin A. Lee, the co-founder and director of Project CBD. In addition to creating content for the Project CBD website and speaking at conferences around the globe, Martin has authored several books, including Smoke Signals: A Social History of Marijuana–Medical, Recreational and Scientific. In fact, we have a copy in our Medicinal Genomics office.   

Martin and I discussed the topic everyone is talking about, COVID-19. Martin has reviewed the scientific literature to find out whether CBD can calm the cytokine storm that the COVID virus can set off, whether CBD has anti-viral properties, and if cannabis is an immune system booster, suppressant, or both. As you can imagine, with a virus as new and novel as COVID-19 and a federal ban on cannabis, the research is far from conclusive. But I think you will see there is some potential and some areas that merit future research. Who knows, maybe we will see some compelling data at a future CannMed event.  

Click the player below to listen, and thanks to our sponsor, Project CBD!

SIGN UP FOR PODCAST UPDATES AND ENTER TO WIN 2 VIP DINNER TICKETS!

Additional Resources:

CANNABIS, CBD & COVID-19 Martin's CannMed 2019 Presentation "Psychedelics & Cannabis Therapeutics"

In this episode of CannMed Coffee Talk we talk with Martin A. Lee, the co-founder and director of Project CBD. In addition to creating content for the Project CBD website and speaking at conferences around the globe, Martin has authored several books, including Smoke Signals: A Social History of Marijuana–Medical, Recreational and Scientific. In fact, we have a copy in our Medicinal Genomics office.   

Martin and I discussed the topic everyone is talking about, COVID-19. Martin has reviewed the scientific literature to find out whether CBD can calm the cytokine storm that the COVID virus can set off, whether CBD has anti-viral properties, and if cannabis is an immune system booster, suppressant, or both. As you can imagine, with a virus as new and novel as COVID-19 and a federal ban on cannabis, the research is far from conclusive. But I think you will see there is some potential and some areas that merit future research. Who knows, maybe we will see some compelling data at a future CannMed event.  

Click the player below to listen, and thanks to our sponsor, Project CBD!

SIGN UP FOR PODCAST UPDATES AND ENTER TO WIN 2 VIP DINNER TICKETS!

Additional Resources:

CANNABIS, CBD & COVID-19 Martin's CannMed 2019 Presentation "Psychedelics & Cannabis Therapeutics"

We are excited to announce CannMed 2020’s Keynote Presenter in the Science Focus Area is Dr. Ethan Russo.

The title of Dr. Russo’s presentation is “Cannabis and Psychiatry: The Final Frontier”, and it will explore basic science and clinical trial data to assess the role of cannabis psychopharmacology with respect to issues of impairment, depression, insomnia, PTSD, schizophrenia, anxiety and addiction.

You can hear about this fascinating topic and more in our latest episode of the CannMed Coffee Talk Podcast, where Dr. Russo joins us as a guest. This is a great episode for listeners who are new to cannabis medicine because Dr. Russo covers some of the basics, like "what is the endocannabinoid system?" Having said that, there is still plenty of meat on the bone for more advanced listeners. Use the player at the bottom at the post to listen.

Dr. Russo began his career as a physician, board-certified in Neurology with a Special Qualification in Child Neurology, but he has always held a strong interest in medicinal plants, which he gradually incorporated into his practice and research endeavors, with the intention of bringing cannabis-based and other botanical agents back into the mainstream of medicine.

He is a graduate of the University of Pennsylvania (Psychology) and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child/Adult Neurology at the University of Washington, and was a clinical neurologist in Missoula, Montana for 20 years.

After his clinical experience, he began dedicating his career to developing innovative approaches targeting the human endocannabinoid system to produce dramatic results for patients suffering from a range of neuro- and immuno-based diseases and disorders.

From 2003 to 2014, Dr. Russo was instrumental in developing both Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals. In 2015, he became Medical Director of PHYTECS, a company devoted to the research and development of medicines, supplements and lifestyle approaches to optimizing the function of the endocannabinoid system (ECS), the critical homeostatic regulatory mechanism of human physiology. From 2015-2017, he was Director of Research and Development for the International Cannabis and Cannabinoids Institute.

Dr. Russo has also held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, the Chinese Academy of Sciences. He is a Past-President of the International Cannabinoid Research Society, and former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council and has published several books, numerous book chapters, and over forty articles in neurology, pain management, cannabis, and ethnobotany, and he has consulted or lectured on these topics in more than 30 US states and 30 countries.

His current venture, called CReDO Science, aims to advance cannabis-based and botanical therapeutics via the development of optimized chemovars and extracts, as well as pursuing novel formulations and diagnostics related to the endocannabinoid system. More information can be found by visiting https://credo-science.com.

Needless to say, we are delighted to have him as such an important part of CannMed 2020.

SIGN UP FOR PODCAST UPDATES AND ENTER TO WIN 2 VIP DINNER TICKETS!

Related Links:

Ethan Russo, MD CannMed 2018 PresentationEthan Russo, MD ResearchGate ProfileCReDO Science LLC Website

We are excited to announce CannMed 2020’s Keynote Presenter in the Science Focus Area is Dr. Ethan Russo.

The title of Dr. Russo’s presentation is “Cannabis and Psychiatry: The Final Frontier”, and it will explore basic science and clinical trial data to assess the role of cannabis psychopharmacology with respect to issues of impairment, depression, insomnia, PTSD, schizophrenia, anxiety and addiction.

You can hear about this fascinating topic and more in our latest episode of the CannMed Coffee Talk Podcast, where Dr. Russo joins us as a guest. This is a great episode for listeners who are new to cannabis medicine because Dr. Russo covers some of the basics, like "what is the endocannabinoid system?" Having said that, there is still plenty of meat on the bone for more advanced listeners. Use the player at the bottom at the post to listen.

Dr. Russo began his career as a physician, board-certified in Neurology with a Special Qualification in Child Neurology, but he has always held a strong interest in medicinal plants, which he gradually incorporated into his practice and research endeavors, with the intention of bringing cannabis-based and other botanical agents back into the mainstream of medicine.

He is a graduate of the University of Pennsylvania (Psychology) and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child/Adult Neurology at the University of Washington, and was a clinical neurologist in Missoula, Montana for 20 years.

After his clinical experience, he began dedicating his career to developing innovative approaches targeting the human endocannabinoid system to produce dramatic results for patients suffering from a range of neuro- and immuno-based diseases and disorders.

From 2003 to 2014, Dr. Russo was instrumental in developing both Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals. In 2015, he became Medical Director of PHYTECS, a company devoted to the research and development of medicines, supplements and lifestyle approaches to optimizing the function of the endocannabinoid system (ECS), the critical homeostatic regulatory mechanism of human physiology. From 2015-2017, he was Director of Research and Development for the International Cannabis and Cannabinoids Institute.

Dr. Russo has also held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, the Chinese Academy of Sciences. He is a Past-President of the International Cannabinoid Research Society, and former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council and has published several books, numerous book chapters, and over forty articles in neurology, pain management, cannabis, and ethnobotany, and he has consulted or lectured on these topics in more than 30 US states and 30 countries.

His current venture, called CReDO Science, aims to advance cannabis-based and botanical therapeutics via the development of optimized chemovars and extracts, as well as pursuing novel formulations and diagnostics related to the endocannabinoid system. More information can be found by visiting https://credo-science.com.

Needless to say, we are delighted to have him as such an important part of CannMed 2020.

SIGN UP FOR PODCAST UPDATES AND ENTER TO WIN 2 VIP DINNER TICKETS!

Related Links:

Ethan Russo, MD CannMed 2018 PresentationEthan Russo, MD ResearchGate ProfileCReDO Science LLC Website

We have a great episode for you today featuring Medicinal Genomics Chief Scientific Officer Kevin McKernan. Kevin is a legend in the genomic sequencing space going back to his days working on the human genome project. He has applied his experience and knowledge to trying to better understand the cannabis genome, which as he mentions in the episode is one of the hardest genomes to figure out. So much so that many of the top names in genetic sequencing have collaborated to try and solve the problem. 

If you aren’t familiar with sequencing terminology you may not understand all of the information Kevin drops, and it’s a lot, but safe to say his efforts and those of his collaborators will benefit everyone in the community. With a solid understanding of the cannabis genome, cannabis and hemp breeders can create plants that can better produce the compounds needed to treat patients in need.  

In time, they may also find markers for better yield and pathogen resistance that can drive down the cost of cannabis so it is more accessible. 

This is just another example of how cannabis scientists, clinicians and cultivators can all learn from one another at CannMed 2020. If you would like to join us at Pasadena this September, now is a great time to get your ticket!

SIGN UP FOR PODCAST UPDATES AND ENTER TO WIN 2 VIP DINNER TICKETS!

Links to learn more about Kevin and his genetic sequencing work:

Kevin's CannMed Presentations: 2019 | 2018 | 2017 Sequence and annotation of 42 cannabis genomes reveals extensive copy number variation in cannabinoid synthesis and pathogen resistance genesCryptofunded Cannabis Genomes Kannapedia.net StrainSEEK Strain Identification and Registration Service Medicinal Genomics' Cannabis Genetics YouTube Playlist

We have a great episode for you today featuring Medicinal Genomics Chief Scientific Officer Kevin McKernan. Kevin is a legend in the genomic sequencing space going back to his days working on the human genome project. He has applied his experience and knowledge to trying to better understand the cannabis genome, which as he mentions in the episode is one of the hardest genomes to figure out. So much so that many of the top names in genetic sequencing have collaborated to try and solve the problem. 

If you aren’t familiar with sequencing terminology you may not understand all of the information Kevin drops, and it’s a lot, but safe to say his efforts and those of his collaborators will benefit everyone in the community. With a solid understanding of the cannabis genome, cannabis and hemp breeders can create plants that can better produce the compounds needed to treat patients in need.  

In time, they may also find markers for better yield and pathogen resistance that can drive down the cost of cannabis so it is more accessible. 

This is just another example of how cannabis scientists, clinicians and cultivators can all learn from one another at CannMed 2020. If you would like to join us at Pasadena this September, now is a great time to get your ticket!

SIGN UP FOR PODCAST UPDATES AND ENTER TO WIN 2 VIP DINNER TICKETS!

Links to learn more about Kevin and his genetic sequencing work:

Kevin's CannMed Presentations: 2019 | 2018 | 2017 Sequence and annotation of 42 cannabis genomes reveals extensive copy number variation in cannabinoid synthesis and pathogen resistance genesCryptofunded Cannabis Genomes Kannapedia.net StrainSEEK Strain Identification and Registration Service Medicinal Genomics' Cannabis Genetics YouTube Playlist

Medicinal Genomics invites you to listen to our new CannMed Coffee Talk Podcast. Each episode we talk with the leading minds in cannabis science, medicine, cultivation, and safety testing, discussing topics from the bench to the bedside.

Don't miss this opportunity to get a sneak-peek into the 4 FOCUS AREAS that will be covered at CannMed 2020 in Pasadena, CA on September 20-22, 2020.

Medicinal Genomics invites you to listen to our new CannMed Coffee Talk Podcast. Each episode we talk with the leading minds in cannabis science, medicine, cultivation, and safety testing, discussing topics from the bench to the bedside.

Don't miss this opportunity to get a sneak-peek into the 4 FOCUS AREAS that will be covered at CannMed 2020 in Pasadena, CA on September 20-22, 2020.